natgillin/translations-raw huggingface dataset:
Pri bolnikih s patološkim izhodiščnim kreatininom (> 1,4 mg/dl ali > 124 mikromolov/l), zvišanje za 1,0 mg/dl ali 88 mikromolov/l.
For patients with abnormal baseline creatinine (> 1.4 mg/dl or > 124 micromol/l), an increase of 1.0 mg/dl or 88 micromol/l.
Pri bolnikih s povišano telesno temperaturo, nevtropenijo in odgovarjajočo obliko bolečine v trebuhu je treba pomisliti na možnost nevtropeničnega kolitisa.
In patients presenting with fever, neutropenia, and a compatible pattern of abdominal pain, the possibility of neutropenic colitis should be considered.
Pri bolnikih s pozitivnim izvidom na protitelesa proti ustekinumabu je bila učinkovitost zdravljenja manjša, vendar pozitiven izvid na protitelesa ne pomeni, da se bolnik ni odzval na zdravljenje.
Efficacy tended to be lower in patients positive for antibodies to ustekinumab; however, antibody positivity did not preclude a clinical response.
Pri bolnikih s psoriatičnim artritisom ali Crohnovo boleznijo sočasna uporaba MTX, NSAID, 6-merkaptopurina, azitioprina in peroralnih kortikosteroidov ali predhodna izpostavljenost zaviralcem TNFα ni vplivala na farmakokinetiko ustekinumaba.
The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis or Crohn’s disease.
Pri bolnikih s psoriazo je sistemska izpostavljenost ustekinumabu (Cmax in AUC) po enkratni intravenski injekciji odmerkov od 0,09 mg/kg do 4,5 mg/kg ali po enkratni subkutani injekciji odmerkov od približno 24 mg do 240 mg naraščala približno sorazmerno z odmerkom.
The systemic exposure of ustekinumab (Cmax and AUC) increased in an approximately dose-proportional manner after a single intravenous administration at doses ranging from 0.09 mg/kg to 4.5 mg/kg or following a single subcutaneous administration at doses ranging from approximately 24 mg to 240 mg in patients with psoriasis.
Pri bolnikih s psoriazo s plaki se med potekom bolezni lahko razvije eritrodermična psoriaza s simptomi, ki jih klinično ni mogoče ločiti od simptomov eksfoliativnega dermatitisa.
Patients with plaque psoriasis may develop erythrodermic psoriasis, with symptoms that may be clinically indistinguishable from exfoliative dermatitis, as part of the natural course of their disease.
Pri bolnikih s psoriazo so po zdravljenju z ustekinumabom poročali o eksfoliativnem dermatitisu (glejte poglavje 4.8).
In patients with psoriasis, exfoliative dermatitis has been reported following ustekinumab treatment (see section 4.8).
Pri bolnikih s spremljajočimi dejavniki tveganja je pred začetkom zdravljenja z difosfonati priporočeno opraviti zobozdravniški pregled z ustreznimi preventivnimi zobozdravstvenimi ukrepi in oceniti razmerje med koristmi in tveganji pri vsakem posameznem bolniku.
A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphosphonates in patients with concomitant risk factors.
Pri bolnikih s sumom na atipičen zlom stegnenice je treba razmisliti o prenehanju zdravljenja z difosfonatom dokler ni opravljena ocena bolnikovega stanja; pri tem je treba upoštevati individualno oceno koristi in tveganja.
Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.
Pri bolnikih s telesno maso > 100 kg je odmerek lahko 90 mg.
Alternatively, 90 mg may be used in patients with a body weight > 100 kg.
Pri bolnikih s TIH in hudo okvaro ledvic pride zdravljenje z zdravilom Zoledronska kislina Actavis v poštev šele po oceni tveganj in koristi zdravljenja.
Zoledronic acid Actavis treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Pri bolnikih v študiji UNITI-1 predhodno zdravljenje z zaviralci TNFα ni bilo uspešno ali pa ga niso prenašali.
Patients in UNITI-1 had failed or were intolerant to prior anti-TNFα therapy.
Pri bolnikih v študiji UNITI-2 je bilo neuspešno najmanj eno konvencionalno zdravljenje (vključno s kortikosteroidi ali imunomodulatorji) in se še niso zdravili z zaviralci TNFα (68,6%) ali pa so se zdravili z zaviralci TNFα in se na zdravljenje niso odzvali (31,4%).
Patients in UNITI-2 had failed at least one conventional therapy, including corticosteroids or immunomodulators, and were either anti-TNF-α naïve (68.6%) or had previously received but not failed anti-TNFα therapy (31.4%).
Pri bolnikih z akutnim koronarnim sindromom:
In patients suffering from acute coronary syndrome:
Pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina 45 – 79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID-i (denimo, ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or aspirin at higher doses should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blago ledvično okvaro se ne priporočajo nobene spremembe standardnega odmerka (glejte poglavje 5.2).
No adjustment of the standard dose is recommended in patients with mild renal impairment (see section 5.2).
Pri bolnikih z entezitisom in daktilitisom na začetku zdravljenja z ustekinumabom so v 1. študiji PsA po 24 tednih zdravljenja opažali pomembno izboljšanje ocene entezitisa in daktilitisa v primerjavi z bolniki, ki so prejemali placebo.
For patients with enthesitis and/or dactylitis at baseline, in PsA Study 1 significant improvement in enthesitis and dactylitis score was observed in the ustekinumab groups compared with placebo at week 24.
Pri bolnikih z jetrno okvaro odmerjanja ni potrebno prilagajati.
No dose adjustment is necessary for patients with impaired hepatic function.
Pri bolnikih z jetrno okvaro se ne priporočajo nobene spremembe standardnega odmerka (glejte poglavje 5.2).
No adjustment of the standard dose is recommended for patients with hepatic impairment (see section 5.2).
Pri bolnikih z latentno tuberkulozo, ki so bili sočasno zdravljeni z izoniazidom, se v kliničnih študijah ni pojavila tuberkuloza.
In clinical studies, patients with latent tuberculosis who were concurrently treated with isoniazid did not develop tuberculosis.
Pri bolnikih z ledvično insuficienco ni potrebno prilagajati odmerka.
No dosage adjustment is necessary in patients with renal insufficiency.
Pri bolnikih z ledvično okvaro odmerjanja ni potrebno prilagajati.
No dose adjustment is necessary for patients with impaired renal function.
Pri bolnikih z majhnim številom trombocitov je nevarnost krvavitve povečana, zato jih je treba skrbno spremljati.
Patients with low platelet counts are at increased risk for bleeding and should be monitored carefully.
Pri bolnikih z multiplim mielomom se utegne lahko tveganje za moteno delovanje ledvic poveča, če je zdravilo Zoledronska kislina Actavis uporabljeno v kombinaciji s talidomidom.
In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid Actavis is used in combination with thalidomide.
Pri bolnikih z napredovalo Parkinsonovo boleznijo, ki jemljejo zdravilo v kombinaciji z levodopo, se lahko med začetnim stopnjevanjem odmerka zdravila Pramipeksol Accord pojavijo diskinezije.
In advanced Parkinson’s disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of Pramipexole Accord.
Pri bolnikih z nezaceljenimi odprtimi lezijami mehkih tkiv v ustih je treba začetek zdravljenja oziroma nov ciklus zdravljenja odložiti, razen v primeru nujnih stanj.
The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth, except in medical emergency situations.
Pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina ≥ 80 ml/min) lahko visoki odmerki nesteroidnih protivnetnih zdravil (NSAID-i, denimo, ibuprofen > 1600 mg dnevno) in acetilsalicilna kislina v visokih odmerkih (≥ 1,3 g dnevno) zmanjšajo eliminacijo pemetrekseda in tako lahko povečajo pojavnost neželenih učinkov pemetrekseda.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher doses (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Pri bolnikih z očistkom kreatinina nad 50 ml/min ni potrebno zmanjšati dnevnega odmerka ali pogostnosti odmerjanja.
Patients with a creatinine clearance above 50 ml/min require no reduction in daily dose or dosing frequency.
Pri bolnikih z rakom je delovanje imunskega sistema pogosto oslabljeno.
Immunodepressed status is common in cancer patients.
Pri bolnikih z rakom želodca povezava med občutljivostjo za 5-FU in vrednostjo MSI ni jasna, povezava med zdravilom Teysuno in vrednostjo MSI pri raku želodca pa je neznana.
The association between 5-FU sensitivity and MSI in patients with gastric cancer is unclear and the association between Teysuno and MSI in gastric cancer is unknown.
Pri bolnikih z zmerno hudo ledvično okvaro se je plazemski očistek zmanjšal na 34 % vrednosti pri bolnikih v kontrolni skupini.
In patients with moderate renal impairment topotecan plasma clearance was reduced to 34 % of the value in control patients.
Pri bolnikih z zmerno ledvično okvaro (CrCl 30–50 ml/min), ki so dvakrat dnevno prejemali zmanjšan odmerek 20 mg/m2, niso opazili izrazitega povečanja povprečja AUC0-inf za 5-FU v primerjavi s povprečjem v normalni skupini.
Patients with moderate renal impairment (CrCl 30 to 50 ml/min) who received a reduced dose of 20 mg/m2 twice daily showed no significant increase in mean 5-FU AUC0-inf relative to that of the normal group.
Pri bolnikih z zmerno okvaro jeter je potrebna previdnost.
Caution should be exercised if patients have moderate hepatic disease
Pri bolnikih, ki bodo premeščeni v drugo bolnišnico, zagotovite možnost dovajanja dušikovega oksida med prevozom, da preprečite poslabšanje zdravstvenega stanja ob nenadni prekinitvi dovajanja zdravila INOmax.
For patients who are to be referred to another hospital, to prevent worsening of their condition on acute discontinuation of INOmax, the availability of nitric oxide during transport should be assured.
Pri bolnikih, ki bodo zaradi dodatnega zdravljenja premeščeni v druge ustanove in ki morajo še naprej vdihovati dušikov oksid, poskrbite, da bodo med prevozom imeli neprekinjeno dovajanje dušikovega oksida.
For patients transported to other facilities for additional treatment, who need to continue with inhaled nitric oxide, arrangements should be made to ensure the continuous supply of inhaled nitric oxide during transportation.
Pri bolnikih, ki imajo rak želodca in MSI, še niso izvedli nobenih študij za zdravilo Teysuno.
Teysuno has not been studied in gastric cancer patients with MSI.
Pri bolnikih, ki pred zdravljenjem niso prejemali kortikosteroidov, so poročali o kožnih reakcijah.
Skin reactions have been reported in patients not pre-treated with a corticosteroid.
Pri bolnikih, ki prejemajo to kombinacijo, je priporočeno spremljanje kliničnih in biokemičnih parametrov.
Clinical and biochemical monitoring of patients receiving this combination is recommended.
Pri bolnikih, ki prejemajo zdravilo Teysuno v kombinaciji s cisplatinom, so poročali o neželenih učinkih stopnje 3. ali višje stopnje, kot so zvišanje kreatinina v krvi, zmanjšan očistek kreatinina, toksična nefropatija in akutna odpoved ledvic (glejte poglavje 4.8).
Adverse reactions of Grade 3 or higher such as increased blood creatinine, decreased creatinine clearance, toxic nephropathy, and acute renal failure have all been reported in patients receiving Teysuno in combination with cisplatin (see section 4.8).
Pri bolnikih, ki se do 28. tedna niso odzvali na zdravljenje, je treba razmisliti o prekinitvi zdravljenja.
Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment.
Pri bolnikih, ki se do 28. tedna niso odzvali na zdravljenje, je treba razmisliti o ukinitvi zdravljenja.
Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment.
Pri bolnikih, ki se zdravijo s kemoterapijo in/ali obsevanjem, ki jemljejo steroide, imajo zobozdravstveno operacijo, ki nimajo redne zobozdravstvene oskrbe, ki imajo obolenje dlesni, ki kadijo ali ki so se v preteklosti zdravili z difosfonati (uporabljajo se za zdravljenje ali preprečevanje obolenj kosti), je lahko tveganje za pojav osteonekroze čeljustnic večje.
Patients who are undergoing chemotherapy and/or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate (used to treat or prevent bone disorders) may have a higher risk of developing osteonecrosis of the jaw.
Pri bolnikih, ki so bili zdravljeni z zoledronsko kislino, so poročali o hipokalciemiji.
Hypocalcaemia has been reported in patients treated with zoledronic acid.
Pri bolnikih, ki so jemali fenofibrat ali pravastatin, so poročali o pankreatitisu (glejte poglavje 4.3).
Pancreatitis has been reported in patients taking fenofibrate or pravastatin (see sections 4.3).
Pri bolnikih, ki so prejeli samo eno epizodo PDT, je bilo tveganje razvoja raka večje kot pri bolnikih, ki so prejeli 2 ali 3 epizode PDT (50% proti 39 oz.
Patients who received one course of PDT had a greater risk of progression to cancer than patients who received two or three courses of PDT (50% vs.
Pri bolnikih, ki so prejemali to kombinacijo, so poročali o rabdomiolizi (vključno s smrtnimi izidi) (glejte poglavje 4.5).
There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination (see section 4.5).
Pri bolnikih, ki so prejemali to kombinacijo, so poročali o rabdomiolizi (vključno s smrtnimi izidi).
There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.
Pri bolnikih, ki so se odzvali na zdravljenje z zdravilom STELARA, bo morda treba zmanjšati odmerek kortokosteroida ali ga ukiniti, skladno z ustaljeno klinično prakso.
In patients who have responded to treatment with STELARA, corticosteroids may be reduced or discontinued in accordance with standard of care.
Pri bolnikih, ki so se zdravili s permetreksedom, so redko poročali o imunsko pogojeni hemolitični anemiji.
Rarely, immune-mediated haemolytic anaemia has been reported in patients treated with pemetrexed.
Pri bolnikih, ki so se zdravili s topotekanom v kombinaciji s cisplatinom, je bila celotna hematološka toksičnost manjša kot pri samostojnem zdravljenju s topotekanom, vendar večja kot pri samostojnem zdravljenju s cisplatinom.
The overall haematological toxicity is lower in patients treated with topotecan in combination with cisplatin compared to topotecan monotherapy, but higher than with cisplatin alone.
Pri bolnikih, ki so se zdravili s topotekanom, so poročali o mielosupresiji, ki je povzročila sepso in smrti zaradi sepse (glejte poglavje 4.8).
Myelosuppression leading to sepsis and fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.8).
Pri bolnikih, ki so se zdravili z dopaminskimi agonisti, tudi zdravilom Pramipeksol Accord, se lahko pojavijo patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno trošenje denarja ali nakupovanje, prenajedanje in kompulzivno uživanje hrane (glejte poglavje 4.4).
Pathological gambling, increased libido, hypersexuality, , compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Pramipexole Accord. (see section 4.4).
Pri bolnikih, ki so se zdravili z zdravilom Zoledronska kislina Actavis, so poročali o znižani koncentraciji kalcija v krvi (hipokalciemiji), zaradi katere v nekaterih primerih lahko pride do mišičnih krčev, suhe kože in pekočega občutka.
Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with zoledronic acid.
Pri bolnikih, ki so starejši od 75 let, je treba zdravljenje s klopidogrelom začeti brez udarnega odmerka.
For patients over 75 years of age clopidogrel should be initiated without a loading dose.
Pri bolnikih, ki so stari 70 let ali več, se ne priporočajo nobene spremembe standardnega odmerka (glejte poglavje 4.8).
No adjustment of the standard dose is recommended in patients >70 years old (see section 4.8).
Pri bolnikih, pri katerih ni odziva do 28. tedna, je potrebno razmisliti o prekinitvi zdravljenja.
Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment.
Pri bolnikih, pri katerih opravljajo srčni kirurški poseg, so pogosto opazili povišanje tlaka v pljučni arteriji zaradi pljučne vazokonstrikcije.
In patients undergoing heart surgery, an increase in pulmonary artery pressure due to pulmonary vaso- constriction is frequently seen.
Pri bolnikih, pri katerih se oceni, da je sistemska uporaba fusidne kisline nujna, je treba prekiniti zdravljenje s statini za celotno obdobje zdravljenja s fusidno kislino.
In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment.
Pri bolnikih, pri katerih zdravimo nedrobnocelični pljučni karcinom po predhodni kemoterapiji, je priporočeni odmerek zdravila Pemetreksed Hospira 500 mg/m2 TP, dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega ciklusa.
In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed Hospira is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Pri bolnikih, starejših od 75 let, so na voljo le omejeni podatki o varnosti, zato je potrebna previdnost.
Limited safety data on Pravafenix is available in patients >75 years of age and care should be exercised.
Pri bolnikih, zdravljenih s pemetreksedom, so poročali o občasnih primerih edema.
Uncommon cases of oedema have been reported in patients treated with pemetrexed.
Pri bolnikih, zdravljenih z ustekinumabom, je bilo v študijah UNITI-1 in UNITI-2 po 8 tednih statistično značilno večje in klinično pomembno izboljšanje po vprašalniku IBDQ in SF-36 povzetek ocene duševnih komponent (SF-36 Mental Component Summary Score); ter SF-36 povzetek ocene telesnih komponent (SF-36 Physical Component Summary Score) v študiji UNITI-2, v primerjavi s placebom.
At week 8, patients receiving ustekinumab showed statistically significantly greater and clinically meaningful improvements on IBDQ total score and SF-36 Mental Component Summary Score in both UNITI-1 and UNITI-2, and SF-36 Physical Component Summary Score in UNITI-2, when compared to placebo.
Pri bolnikih, zdravljenih z zdravilom Teysuno v kombinaciji s cisplatinom, so poročali o centralni in periferni nevropatiji.
Central and peripheral neuropathy has been reported in patients treated with Teysuno in combination with cisplatin.
Pri bolnikih, zdravljenih z zdravilom Teysuno v kombinaciji s cisplatinom, so poročali o supresiji kostnega mozga, povezani z zdravljenjem, vključno z nevtropenijo, levkopenijo, trombocitopenijo, anemijo in pancitopenijo.
Treatment-related bone marrow suppression, including neutropaenia, leukopaenia, thrombocytopaenia, anaemia, and pancytopaenia, has been reported among patients treated with Teysuno in combination with cisplatin.
Pri dajanju v kombinaciji s cisplatinom (cisplatin 1. dan, topotekan od 1. do 5. dne) je bil 5. dan očistek topotekana v primerjavi s 1. dnem manjši (19,1 l/uro/m2 v primerjavi s 21,3 l/uro/m2
When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m2 compared to
Pri dajanju zdravila Zoledronska kislina Actavis skupaj z zdravili, za katera je znano, da povzročajo hipokalciemijo, je potrebna previdnost, saj lahko delujejo sinergistično in povzročijo hudo hipokalciemijo (glejte poglavje 4.5).
Caution is advised when zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5).
Pri dolgotrajnejši izpostavljenosti so opažali zvečanje neželenih učinkov (vseh stopenj).
Increases in adverse reactions (all grades) were observed with longer exposure.
Pri drugih posameznih neželenih učinkih stopnje 3/4/5 pa ni bilo zaznati statistično značilnih razlik pri dolgotrajnejši izpostavljenosti.
No statistically significant differences in any other individual Grade 3/4/5 adverse reactions were seen with longer exposure.
Pri dvainpetdesetih odstotkih bolnikov v skupini, ki je dobivala PDT + OM, je bil ploščatocelični epitelij normalen, medtem ko je bilo pri 59% bolnikov opaziti odsotnost displazije v primerjavi s 7% ter 14% v skupini, ki je dobivala samo OM (p<0,0001).
Fifty-two percent of patients in the PDT + OM group showed normal squamous cell epithelium while 59% had absence of dysplasia compared to 7% and 14% in the OM alone group, respectively (p<0.0001).
Pri enainštiridesetih odstotkih bolnikov je bil opažen normalni ploščatocelični epitelij, pri 49% pa odsotnost displazije.
Forty-one percent of patients showed normal squamous cell epithelium and 49% had absence of dysplasia.
Pri enem bolniku se je pojavila smrtno nevarna dispneja, pri drugih pa ni bilo večjih težav.
One patient experienced life-threatening dyspnoea and the others had no notable complications.
Pri enkratnih in večkratnih 5- in 15-minutnih infundiranjih 2, 4, 8 in 16 mg zoledronske kisline pri 64 bolnikih z metastazami v kosteh so dobili spodnje farmakokinetične podatke, ki so bili neodvisni od odmerka.
Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.
Pri gimeracilu niso opazili nobenega vpliva na ledvični očistek za tegafur, FBAL in 5-FU po uporabi zdravila Teysuno v primerjavi z očistkom po samostojni uporabi tegafurja.
There was no effect of gimeracil on renal clearance of tegafur, FBAL, and 5-FU following administration of Teysuno as compared to their clearance following administration of tegafur alone.
Pri hudi ledvični bolezni je običajni odmerek 1 tableta zdravila Pramipeksol Accord po 0,088 mg na dan.
In severe kidney disease, the usual starting dose is just 1 Pramipexole Accord tablet 0.088 mg a day.
Pri izpostavljenosti za 5-FU niso opazili statistično značilnih razlik med skupinama.
Exposure of 5-FU was not statistically significantly different between the two groups.
Pri jemanju tega zdravila natančno upoštevajte zdravnikova navodila.
Always take this medicine exactly as your doctor has told you.
Pri jemanju zdravila Klopidogrel Teva Pharma B.V. natančno upoštevajte zdravnikova navodila.
Always take this medicine exactly as your doctor or pharmacist has told you.
Pri jemanju zdravila Teysuno natančno upoštevajte navodila zdravnika.
Always take Teysuno exactly as your doctor has told you.
Pri kuncih sicer niso ugotovili teratogenosti ali fetotoksičnosti, ugotovili pa so toksičnost za samice-matere.
Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found.
Pri mačkah so občutljivi mikroorganizmi E. coli, Staphylococcus spp., Pasteurella spp., Proteus spp. in Klebsiella spp. (MIK ≤ 0,5 µg/ml ibafloksacina).
In cats, relevant susceptible micro-organisms are E.coli, Staphylococcus spp., Pasteurella spp., Proteus spp. and Klebsiella spp. (MIC ≤ 0.5 µg ibafloxacin/ml).